MIAMI -- IVAX Diagnostics, Inc. (AMEX:IVD) announced today that, after 27 years of distinguished service on behalf the Company and its subsidiaries, Giorgio D'Urso is resigning as President and Chief Executive Officer of the Company and as a member of the Board of Directors of the Company, effective January 10,...
MIAMI -- IVAX Corporation, a wholly owned subsidiary of Teva Pharmaceutical Industries Limited ("Teva"), announced today that it has commenced an offer to repurchase any and all of its outstanding 4.5% Convertible Senior Subordinated Notes due 2008 (the "Notes"). The indenture governing the Notes requires IVAX to make the offer...
JERUSALEM & MIAMI -- Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) and IVAX Corporation (AMEX:IVX) issued the following statement regarding IVAX' outstanding 1.5% Convertible Senior Notes due 2025, in connection with Teva's pending acquisition of IVAX:
MIAMI -- IVAX Diagnostics, Inc. (AMEX:IVD) announced today that, effective September 17, 2007, Kevin D. Clark has been appointed Chief Operating Officer of IVAX Diagnostics. In addition to serving as Chief Operating Officer of IVAX Diagnostics, Mr. Clark will continue to serve as Chief Operating Officer of ImmunoVision, Inc., IVAX...
JERUSALEM, Israel & MIAMI -- Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) and IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) issued the following statement regarding IVAX' outstanding 1.5% Convertible Senior Notes due 2025, in connection with Teva's pending acquisition of IVAX:
JERUSALEM, Israel and MIAMI -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and IVAX Corporation (AMEX: IVX) issued the following statement regarding election procedures for holders of IVAX' outstanding convertible notes, in connection with Teva's pending acquisition of IVAX:
MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) announced today that it has received final approval from the U.S. Food and Drug Administration FDA for its Abbreviated New Drug Application ANDA for clozapine tablets USP, 200 mg. This product will be sold through IVAX' wholly owned subsidiary, IVAX Pharmaceuticals, Inc. Clozapine...
MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX), announced today that it has commenced an offer to repurchase any and all of its outstanding 4.5% Convertible Senior Subordinated Notes due 2008 (the "Notes"). The indenture governing the Notes requires IVAX to make the offer as a result of the approval by...
Miami-based pharmaceutical giant Ivax Corp. was acquired by Teva Pharmaceutical Industries Ltd. of Tel Aviv, Israel for $7.4 billion. The merger gives TEVA operations in more than 50 countries and approximately 25,000 employees. Ivax was one of South Florida's few public Fortune 500 firms.
MIAMI -- At the request of The American Stock Exchange, IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) announced today that an overwhelming majority of shareholders who made their elections prior to yesterday's deadline for making a cash or stock election under the merger agreement elected to receive stock consideration (0.8471 of a...
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c26870) has announced the addition of IVAX Corporation Deals Briefing to their offering
MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) is scheduled to make a presentation Tuesday, June 14, 2005, at 2:00 PM Pacific Time (5:00 PM Eastern Time) at the Twenty Sixth Annual Goldman Sachs Global Healthcare Conference being held at the Ritz Carlton Laguna Niguel in Dana Point, California. Neil Flanzraich,...
MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX), commenting upon the U.S. District Court for the District of Northern Illinois decision to grant Abbott Laboratories Inc.'s motion for a preliminary injunction against sales by Teva Pharmaceutical Industries Ltd. of its generic version of extended release antibiotic BiaxinR, states that this decision...
MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) is scheduled to make a presentation Wednesday, June 1, 2005, at 10:20 AM Eastern Time at the Friedman Billings Ramsey 9th Annual Growth Conference being held at the Millennium Broadway Hotel in New York. Neil Flanzraich, vice chairman and president of IVAX Corporation,...
JERUSALEM -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) issued the following statement regarding the outstanding 1.5% Convertible Senior Notes due 2025 of Ivax Corporation, in connection with Teva's pending acquisition of Ivax.
MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) announced today that it will donate $500,000 in cash and pharmaceutical products to the victims of Hurricane Katrina. IVAX' cash contribution will be made to the Salvation Army. IVAX' pharmaceutical product contribution will be made in collaboration with five major pharmacy chains to...
MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) announced today that the Federal District Court in New Jersey granted a motion by IVAX for summary judgment of noninfringement of Pfizer's U.S. patent No 6,054,482 for NeurontinR.
MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) is scheduled to make a presentation Tuesday, April 5, 2005, at 4:15 PM Eastern Time at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference being held at The Millennium Broadway Hotel in New York City. Neil Flanzraich, vice chairman and president...
MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) received final Marking Authorization approval from the Medicine and Healthcare Products Regulatory Agency for fluticasone nasal spray. Fluticasone is the generic equivalent of FlixonaseR (known in the U.S. as FlonaseR) and marketed by GlaxoSmithKline for the treatment of rhinitis. IVAX' generic equivalent of...